Aiforia Technologies Plc, Press Release, April 27, 2026 at 9:00 a.m. EEST
Aiforia Technologies Plc announced today that Fimlab Laboratories in Finland has expanded the use of Aiforia’s AI solutions in routine clinical workflow. Already in 2025, as part of the first deployment batch under the framework agreement, Fimlab implemented Aiforia’s breast cancer diagnostics solution – a complete suite for both breast cancer grading and biomarker panels. Now, Fimlab Laboratories has also implemented a bespoke AI solution, tailored specifically for their needs, to bring multi-organ Ki67 biomarker quantification into routine clinical use.
The Ki67 protein is a crucial marker in cancer diagnostics for measuring cell proliferation. Its presence indicates how aggressively a tumor is growing, which is essential for determining a patient’s treatment path. This new solution brings the AI-driven precision already used in Ki67 analysis for breast cancer to a wide array of other tumor types, such as thyroid tumors, neuroendocrine tumors of the gastrointestinal tract, pancreas and lung, and other tumors.
"Encouraged by the results obtained in breast cancer diagnostics, we are expanding the use of Aiforia's AI-assisted Ki67 analysis from breast cancer to several other cancer types. With the new AI solution, we will further streamline the diagnostic workflow and shorten turnaround times for examinations. Furthermore, we will gain accurate information about the nature of the tumors, which aids us diagnostically and helps our clients specify treatment processes," says Mika Tirkkonen, Chief of Pathology at Fimlab.
“This progress at Fimlab perfectly demonstrates our strong partnership, showcasing how close collaboration allows us to create and implement custom, high-impact AI solutions tailored to our customers' evolving clinical needs. Expanding the AI-assisted Ki67 quantification from breast cancer to a multi-organ panel illustrates the adaptability of our platform and our commitment to co-developing tools that boost precision and efficiency across various clinical workflows”, says Jukka Tapaninen, CEO of Aiforia.
Fimlab is Finland’s largest healthcare laboratory company, owned by the wellbeing services counties of Pirkanmaa, Central Finland, Kanta-Häme, Ostrobothnia, and Päijät-Häme. It serves a population of approximately 1.5 million people.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com
Back to all blog posts
